

In silico validation of motion-including dose reconstruction for MR-guided lung SBRT using a patient specific motion model

J Bertholet^{†1}, B Eiben², MJ Menten¹, EH Tran², DJ Hawkes², Andreas Wetscherek¹, S Nill¹, JR McClelland² and U Oelfke¹

¹Joint Department of Physics, the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK. ²Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, UK.

Introduction

Motion-including dose reconstruction (MIDR) aims at reconstructing the actually delivered dose to the moving anatomy during radiotherapy. However, the time-resolved patient anatomy during treatment is generally unknown. Patient specific motion models (PSMM) built on MR imaging can be used to estimate the time-resolved anatomy during treatment delivery with simultaneous MR imaging on an MR-linac. In this study, a digital 4D phantom was used to validate PSMM-based MIDR for MR-guided lung SBRT.

Materials & Methods

Data. The digital XCAT phantom¹ was used to create a reference anatomy with a lung tumour and corresponding deformable vector fields (DVF) for diaphragm and chest motion traces measured *in vivo* in a volunteer. The DVFs were smoothed, inverted, and used to warp the reference anatomy to produce the ground truth time-resolved anatomy (GT-XCAT) with CT-contrast as well as with MR-contrast (fig1.a).




Figure 1: (a) Pre-treatment: GT-data generation and PSMM building. (b) MR acquisition sequence.

Workflow. Pre-treatment: GT-XCAT were generated for the first 10 minutes of the motion traces. The MR-contrast volumes were subsampled to simulate an interleaved sagittal/coronal MR acquisition with a sagittal surrogate slice (fig1.b). The skin and diaphragm motion were extracted from the surrogate slices and used as breathing signals to simultaneously fit a PSMM and reconstruct a motion-compensated super-resolution image (MCSRI)². An MR-linac treatment plan for 3-fraction lung-SBRT was designed (9 beams step-and-shoot IMRT, 54 Gy to 95% of the PTV, 7MV) on a reference GT-XCAT with CT-contrast. Intra-treatment: GT-XCAT were generated for the remainder of the motion traces as for pre-treatment (fig1.a). The time-resolved deformations of the MCSRI were estimated by the PSMM using the breathing signals extracted from surrogate slices sub-sampled from GT-XCATs every 0.3s. The reference XCAT anatomy was registered to the MCSRI and deformed to obtain the time-resolved PSMM anatomy with CT-contrast. Treatment delivery was simulated in our in-house emulator³ updated with an Elekta Unity MR-linac model.

MIDR: The treatment fluence was discretized into sub-beams, each associated with the GT or deformed MCSRI anatomy that it was delivered to. The dose on each anatomy was calculated in a TPS with a Monte Carlo dose engine (2% uncertainty per calculation) and accumulated onto the reference anatomy using GT-XCAT-DVFs or PSMM-DVFs and direct dose mapping. For comparison, shift-MIDR was calculated emulating tumour motion as sub-beam isocenter shifts on the static reference XCAT anatomy⁴.

Results

The difference between GT-MIDR and the plan dose illustrates the motion-induced target underdosage as well as noticeable differences in OAR doses (fig2. top). Evaluated against GT-MIDR, PSMM-MIDR was more accurate than shift-MIDR for OAR dose estimation and similar for target dose estimation (fig2.)




Figure 2: Top: GT-MIDR – plan shows an underdosage of the tumour and hotspots at the heart and the liver. Middle: PSMM – GT-MIDR. Bottom: Shift – GT-MIDR. Yellow (resp. blue) colour indicates that PSMM/shift-MIDR is hotter (resp. colder) than the GT. Table: DVH endpoints for the plan and MIDR.

Discussion & Conclusions

The presented method allows to validate MIDR for different time-resolved anatomy estimation methods. The PSMM based on interleaved MR acquisition and internal breathing signals extraction was shown to be suitable for MIDR of the target and OAR. Shift-MIDR is not intended to correctly estimate OAR dose⁴ but may be used for target dose estimation with similar accuracy as PSMM-MIDR. PSMM-MIDR may be used for verification of lung-SBRT treatment delivery on the MR-linac.

References

1. Segars et al. Med. Phys. 37, 4902–4915 (2010).
2. McClelland et al. Phys. Med. Biol. 62, 4273–4292 (2017).
3. Fast et al. Med. Phys. 41, 111719 (2014).
4. Poulsen et al. Med. Phys. 39, 6237–6246 (2012).

Acknowledgements

We thank Tom Bruijnen from UMC Utrecht for his help generating MR-contrast XCAT. We acknowledge funding from: CRUK (C33589/A19727 and /A19908); CRUK ART-NET Network Accelerator Award (A21993); NHS funding to the NIHR Biomedical Research Centre at the RMH and the ICR; Elekta AB.

†Corresponding Author: Jenny.bertholet@icr.ac.uk